A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.
Arthritis and Rheumatology.
Times cited: 17
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
The Journal of clinical investigation.
Times cited: 51